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(PL ‑ACS) contains data on both MI and DM 
treatment, as well as in ‑hospital and long ‑term 
outcomes, we decided to analyze the popula‑
tion of diabetic patients with MI. The pur‑
pose of the study was to compare baseline 
characteristics, treatment patterns, and in‑
‑hospital outcomes of patients with and with‑
out DM hospitalized for MI. The second aim 
was to compare hypoglycemic treatment in pa‑
tients with DM with and without left ventric‑
ular systolic dysfunction (LVSD) during hos‑
pitalization and at discharge.
Methods The rationale and methodology of 
PL ‑ACS were described previously.6 At the time of 
this analysis, the registry included 738 790 patients 
with acute coronary syndrome (ACS), of which 
456 381 had MI. The study included patients with 
MI hospitalized between January 2018 and Decem‑
ber 2018. They were divided into 2 groups: patients 
Introduction Diabetes mellitus (DM) is a com‑
mon risk ‑factor for cardiovascular diseases. In pa‑
tients without a history of cardiovascular disease, 
DM is associated with a higher risk of coronary ar‑
tery disease (CAD), coronary death, and nonfatal 
myocardial infarction (MI).1 Patients with at least 
a 10‑year history of DM without any target organ 
damage and with any risk factor other than DM 
are categorized as high ‑risk individuals.2 Diabe‑
tes may be found in 13.7% to 35.6% of patients 
with MI and is associated with worse clinical pa‑
rameters, higher prevalence of comorbidities, and 
a greater extent of CAD.2‑5 These patients are also 
characterized by increased  in ‑hospital mortality, 
both in men (11.7% in DM vs 7.8% in non ‑DM) 
and women (15.6% in DM vs 12.6% in non ‑DM).3
Proper in ‑hospital treatment and treat‑
ment recommended at discharge are of great 
importance in patients with DM. As the Pol‑
ish Registry of Acute Coronary Syndromes 
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in DM patients. No difference in the number 
of patients treated with PCI was found, while 
patients with DM had coronary artery bypass 
grafts and inotropes administered more often 
and glycoprotein IIb / IIIa inhibitors less often. 
Although there was no difference in the sec‑
ond (other than acetylsalicylic acid) antiplatelet 
drug use, clopidogrel was used more often in pa‑
tients with DM, while ticagrelor, in those with‑
out DM. This finding is in contrary to the results 
of the PLATO (Platelet Inhibition and Clinical 
Outcomes) study, which showed that ticagre‑
lor use was associated with less adverse events 
in patients with DM and with better survival, 
with no increase in bleeding.10 This paradox of 
treating sicker patients with the less effective 
drug was described before.11 The latest European 
Society of Cardiology guidelines recommended 
that patients with and without DM should be 
treated according to the same antiplatelet strat‑
egy, and dual antiplatelet therapy with prasug‑
rel or ticagrelor in patients with ACS was supe‑
rior to dual antiplatelet therapy with clopido‑
grel in both DM and non ‑DM groups.2
Patients with DM received at discharge more 
often: β ‑blockers, renin ‑angiotensin ‑aldosterone 
system blockers, mineralocorticoid receptor an‑
tagonists, diuretics, statins, and nitrates. This 
might be associated with more advanced age, 
higher blood pressure, heart rate and lower LVEF. 
The use of antiplatelet drugs at discharge was 
similar in both groups.
In our study patients with DM had higher oc‑
currence of all in ‑hospital adverse events, in‑
cluding in ‑hospital death. This observation is 
consistent with previous studies, in which in‑
‑hospital mortality varied between 1.43% (MUL‑
TIPRAC) and 9.42% (Belgian STEMI) in patients 
with DM and ACS and between 0.34% (MULTIP‑
RAC) and 6.63% (Belgian STEMI) in those with 
ACS but no DM.3,5
Comparing the hospital treatment of DM in 
patients with and without LVSD, patients with 
LVSD received insulin treatment more often, 
while patients without LVSD, oral antidiabetic 
drugs. Similar observations were done at dis‑
charge. During hospitalizations no differenc‑
es in the classes of oral antidiabetic drugs be‑
tween the groups were found. Surprisingly, pa‑
tients with DM and LVSD were more often dis‑
charged without any treatment of DM. Some 
patients with DM were also treated with thia‑
zolidinediones or dipeptidyl peptidase 4 inhib‑
itors, which are suspected to play a role in LVSD 
after MI and are contraindicated in patients 
with reduced LVEF or at high risk of heart fail‑
ure.2,12 Patients with DM and LVSD had higher 
in ‑hospital mortality than those without LVSD 
(9.5% vs 2% respectively; P <0.0001).
According to the Polish summary of product 
characteristics of metformin, it is contraindi‑
cated in patients with heart failure. However, 
with DM and those without. Diabetes was defined 
in the case report form of the registry as history 
of type 2 diabetes before the hospital admission.
Moreover, patients with DM were grouped 
regarding to LVSD. The cutoff for the diagno‑
sis of LVSD was defined as left ventricular ejec‑
tion fraction (LVEF) below 40% on the latest in‑
‑hospital echocardiography.
The study protocol was approved by the eth‑
ics committee, and all patients provided writ‑
ten informed consent to participate in the study.
Statistical analysis Categorical variables were 
presented as percentages. Continuous vari‑
ables with normal distribution were presented 
as mean (SD) and those with other than normal 
distribution, as median and interquartile range 
(IQR). Comparisons between groups were car‑
ried out using the t test or the Mann–Whitney 
test where appropriate. Categorical variables 
were compared with the χ2 test, with the Bon‑
ferroni correction for multiple comparisons and 
the Yates correction in case of small sample size.
Results and discussion We included 25 748 
consecutive patients admitted to the hospital 
with MI between January 2018 and December 
2018 who were reported to the PL ‑ACS registry, 
including 7323 individuals (28.4%) with DM. In 
other ACS registries, the prevalence of DM var‑
ied between 13.7% (MULTIPRAC Registry [Mul‑
tinational Non ‑interventional Study of Patients 
with ST ‑segment Elevation Myocardial Infarc‑
tion Treated with Primary Angioplasty and Con‑
comitant Use of Upstream Antiplatelet Thera‑
py with Prasugrel or Clopidogrel]) and 35.6% 
(CZECH‑2 Registry).5
The baseline characteristics and results were 
presented in TABLE 1 and Supplementary materi‑
al, Table S1. Patients with DM had higher systol‑
ic blood pressure, heart rate, body mass index, 
were more often women, and more often had 
non–ST‑segment elevation myocardial infarc‑
tion.7 The prevalence of comorbidities was high‑
er in the group with DM and more smokers were 
found in the nondiabetic group. These observa‑
tions are consistent with other registries.5 Pa‑
tients with diabetes had higher levels of glucose, 
which is considered to be a risk factor regardless 
of the diabetic or hemodynamic status.8,9 More‑
over, patients with DM had higher levels of tri‑
glycerides, lower levels of cholesterol, worse kid‑
ney function, and lower LVEF. Patients with DM 
were older than those without DM, which is in 
line with other ACS registries, in which patients 
with DM were 64 to 71 years old, and without DM, 
61.7 to 67.6 years old.5 This observation may be 
explained by the fact that in nondiabetic patients, 
the registered MI was more often the first one 
(80.2%) compared with patients with DM (68.2%)
Multivessel CAD and left main CAD were di‑
agnosed more often on coronary angiography 
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TABLE 1 Baseline characteristics, treatment, and outcomes of patients with myocardial infarction and diabetes (continued on the next page)
Parameter DM (n = 7323) No DM (n = 18 425) P value
Baseline characteristics
Age, y, mean (SD) 70.6 (10.0) 66.8 (11.7) <0.001
Male sex 4254 (58.1) 12 463 (67.6) <0.001
Body mass index, kg/m2, median (IQR) 29.4 (6.8) 27.2 (5.7) <0.0001
Main symptom of myocardial infarction Chest pain 6093 (83.2); 7321 16 290 (88.5); 18 417 <0.001
Dyspnea 682 (9.3); 7321 995 (5.4); 18 417
Other 546 (7.5); 7321 1132 (6.1); 18 417
ST ‑elevation myocardial infarction 2234 (30.5) 7040 (38.2) <0.001
Killip class 1 5669 (77.4) 15 701 (85.3) <0.001
2 1134 (15.5) 1975 (10.7)
3 312 (4.3) 334 (1.8)
4 204 (2.8) 398 (2.2)
Systolic blood pressure, mm Hg, median (IQR) 140 (38) 135 (30) <0.001
Diastolic blood pressure, mm Hg, median (IQR) 80 (20) 80 (20) 0.09
Heart rate, bpm, median (IQR) 78 (20) 75 (19) <0.001
Sinus rhythm on admission 6412 (87.7); 7313 16 933 (92); 18 399 <0.001
History of arterial hypertension 6290 (87.4); 7197 11 702 (65.3); 17 920 <0.001
History of hyperlipidemia 3850 (57.3); 6722 7071 (41); 17 245 <0.001
History of coronary artery disease 2435 (34.5); 7057 3506 (19.6); 17 885 <0.001
History of myocardial infarction 2267 (31.8); 7128 3724 (19.8); 18 807 <0.001
History of PCI 2085 (29.3); 7117 3254 (18); 18 075 <0.001
History of CABG 570 (8); 7119 723 (4); 18 081 <0.001
History of atrial fibrillation 1308 (18.4); 7095 2043 (11.3); 18 050 <0.001
History of stroke 624 (8.8); 7093 849 (4.7); 18 055 <0.001
History of heart failure 1143 (17.7); 7024 1600 (8.9); 17 973 <0.001
History of chronic kidney disease 1121 (15.8); 7095 1155 (6.4); 18 040 <0.0001
Smoking 3404 (55.4); 6149 10 469 (64.1); 16 332 <0.001
History of peripheral artery disease 785 (11.2); 7006 965 (5.4); 17 874 <0.001
History of cardiac arrest 191 (2.6); 7310 463 (2.5); 18 389 0.66
Glucose at admission, mmol/l, median (IQR) 9 (5.7) 6.4 (2.2) <0.001
Hemoglobin A1c, %, median (IQR); total 7.2 (2.1); 744 5.7 (0.7); 1187 <0.001
Total cholesterol, mmol/l, mean (SD) 4.4 (1.3) 4.9 (1.4) <0.001
LDL cholesterol, mmol/l, median (IQR) 2.4 (1.6) 2.9 (1.6) <0.001
HDL cholesterol, mmol/l, median (IQR) 1.1 (0.4) 1.2 (0.5) <0.001
Triglycerides, mmol/l, median (IQR) 1.5 (1) 1.2 (0.9) <0.001
eGFR, ml/min/1.73 m2, median (IQR) 73.2 (47.4) 82.2 (44.6) <0.001
LVEF, %, median (IQR) 47 (15) 50 (15) <0.001
LVEDD, mm, median (IQR) 51 (7) 50 (8) <0.001
LVESD, mm, median (IQR) 37 (10) 35 (9) <0.001
NYHA I 3477 (50.3) 10 556 (59.9) <0.001
II 2948 (42.6) 6217 (35.3)
III 423 (6.1) 743 (4.2)
IV 68 (1) 115 (0.6)
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according the international summary of prod‑
uct characteristics, metformin may be used in 
patients with stable chronic heart failure with 
a regular monitoring of cardiac and renal func‑
tion, while it is contraindicated in patients 
with acute and unstable heart failure. Accord‑
ing to the current European Society of Cardiol‑
ogy guidelines, metformin is safe at all stages of 
heart failure with estimated glomerular filtra‑
tion rate greater than 30 ml/min.2 In our study, 
51.6% of diabetic patients with MI and LVEF less 
than 40% had biguanides administered during 
hospital stay and 24.4% at discharge. Metformin 
may reduce the risk of cardiovascular events and 
all ‑cause mortality in patients with MI, as well 
as heart failure.13 Those benefits are not associat‑
ed with the hypoglycemic effects of metformin.14
To conclude, patients with DM were older, had 
more comorbidities, greater CAD extent, and 
more in ‑hospital events. They received the same 
(PCI, antiplatelet drugs) or more intensive (oth‑
er drug classes) treatment than patients without 
DM. Patients with DM and LVSD less often re‑
ceived oral antidiabetic drugs and more often had 
insulin or no antidiabetic treatment administered 
compared with diabetic patients without LVSD.
SUPPLEMENTARY MATERIAL
Supplementary material is available at www.mp.pl/kardiologiapolska.
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TABLE 1 Baseline characteristics, treatment, and outcomes of patients with myocardial infarction and diabetes (continued from the previous page)
Parameter DM (n = 7323) No DM (n = 18 425) P value
In ‑hospital outcomes
Pulmonary edema 139 (1.9); 7265 162 (0.9); 18 267 <0.001
Cardiogenic shock 166 (2.3); 7265 313 (1.7); 18 267 <0.001
Cardiac arrest 223 (3.1); 7263 380 (2.1); 18 267 <0.001
Stroke / transient ischemic attack 34 (0.5); 7263 59 (0.3); 18 265 0.1a
Major bleeding 142 (2); 7264 234 (1.3); 18 267 <0.001
In ‑hospital mortality 370 (5.1); 7323 625 (3.4); 18 425 <0.001
Data are presented as number (percentage); total number of patients for whom data were available unless otherwise indicated.
a Yates correction
Abbreviations: CABG, coronary artery bypass graft; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA1C, glycated hemoglobin; HDL, high ‑density 
lipids cholesterol; LDL, low ‑density lipids cholesterol; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end 
systolic diameter; NYHA, New York Heart Association functional classification
